logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

delete2025-01-01
delete0
PRE
AI
J
Janet McKeown
J
Joe Wei
R
Roma Kankaria
H
Hannah Burnette
D
Douglas B. Johnson
A
Aleigha Lawless
R
Ryan J. Sullivan
L
Lea Jessica Albrecht
L
Lisa Zimmer
J
Joanna Mangana
R
Reinhard Dummer
J
J.I. Kessels
B
Bart Neyns
C
Clara Allayous
C
Célèste Lebbé
C
Christina Boatwright
J
Janice M. Mehnert
M
Margaret Ottaviano
P
Paolo A. Ascierto
A
Anna M. Czarnecka
P
Piotr Rutkowski
S
Serigne Lo
G
Georgina V. Long
A
Alexander M. Menzies
M
Matteo S. Carlino *
DOI：10.1016/j.ejca.2024.115171delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite clinical trial data, little is known about the risk, character, and clinical outcome of late recurrences after ICI. This study aimed to explore the disease outcomes and survival in a cohort of patients with long-term responses to ICI. We retrospectively identified patients treated with ICI for advanced melanoma with long-term disease control, defined as not requiring a subsequent line of systemic therapy within 3 years of ICI commencement. We analysed disease characteristics, treatment, toxicity, recurrence patterns, management, and outcomes. A total of 567 patients were identified with a median follow-up of 7.1 years: 504 (89 %) without disease progression within 3 years (cohort 1) and 63 (11.1 %) with disease progression within 3 years managed without a change in systemic therapy (cohort 2). Subsequent progression after 3 years occurred for 39 (7.7 %) patients in cohort 1, compared to 14 (22 %) in cohort 2. Predictors for late progression after 3 years were a non-complete radiological response (CR) best response and prior progression within 3 years. Thirty-two patients (5.6 %) died during follow-up, 8 (1.4 %) from melanoma, 6 (1.2 %) from cohort 1 and 2 (3.2 %) from cohort 2. In this population of patients with advanced melanoma with long-term disease control from ICI, the risk of subsequent disease progression and death was low. This suggests that a significant proportion of long-term ICI responders are likely cured and may inform the frequency and duration of follow-up.
Keywords:
Melanoma
Immunotherapy
Checkpoint inhibitors
Survival

Journal

European Journal of Cancer cover
European Journal of Cancer
IF:
7.1
Papers:
2.6W
Citations:
3.8W

Organization

No organization information available